Skip to main content
ImmuneCited

Chemoprevention of prostate cancer.

Goutham Vemana, Robert J Hamilton, Gerald L Andriole, Stephen J Freedland
Review Annual review of medicine 2014 9 Zitierungen
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'pmid\u003D24188663'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Studientyp
review
Intervention
Chemoprevention of prostate cancer. None
Vergleichsgruppe
Placebo
Wirkungsrichtung
Mixed
Verzerrungsrisiko
Unclear

Abstract

Large prospective randomized trials, such as the Prostate Cancer Prevention Trial (PCPT), Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, and Selenium and Vitamin E Cancer Prevention Trial (SELECT), have provided practitioners with considerable data regarding methods of treatment and prevention of prostate cancer. The best-studied medications for prevention are 5 alpha-reductase inhibitors. Their efficacy and side effects are well characterized. Other medications, dietary nutrients, and supplements have not been as well studied and generally do not demonstrate efficacy for disease prevention with an acceptable level of evidence.

Used In Evidence Reviews

Similar Papers